P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Sotomi, Yohei; Matsuoka, Yuki; Hikoso, Shungo; Nakatani, Daisaku; Okada, Katsuki; Dohi, Tomoharu; Kida, Hirota; Oeun, Bolrathanak; Sunaga, Akihiro; Sato, Taiki; Kitamura, Tetsuhisa; Sakata, Yasushi

doi:https://doi.org/10.1038/s41598-023-39213-3

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Sotomi, Yohei; Matsuoka, Yuki; Hikoso, Shungo et al.

Scientific Reports, 2023, 13(1), 12608

アクセス数:1,519件（2025-08-16 13:42 集計）

固定URL: https://hdl.handle.net/11094/94602

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
SciRep_13_1_12608	pdf	なし	3.89 MB	91	2024.03.04

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
著者	著者名 Sotomi, Yohei
	著者名 Matsuoka, Yuki
	NRID 1000030423164 1000030423164 researchmap permalink hikoso_osakauniv hikoso_osakauniv 著者名 Hikoso, Shungo
	NRID 1000060444535 1000060444535 researchmap permalink dsyma dsyma Scopus Author ID 6603545219 6603545219 著者名 Nakatani, Daisaku
	NRID 1000020776489 1000020776489 researchmap permalink katsuki_okada katsuki_okada Scopus Author ID 13613369100 13613369100 著者名 Okada, Katsuki
	NRID 1000090838137 1000090838137 researchmap permalink dohi_1230 dohi_1230 Scopus Author ID 35071263000 35071263000 著者名 Dohi, Tomoharu
	著者名 Kida, Hirota
	著者名 Oeun, Bolrathanak
	NRID 1000010812258 1000010812258 researchmap permalink 10812258 10812258 著者名 Sunaga, Akihiro
	著者名 Sato, Taiki
	NRID 1000030639810 1000030639810 ORCID 0000-0003-0107-0580 0000-0003-0107-0580 researchmap permalink Kitamura_T Kitamura_T Scopus Author ID 22234282700 22234282700 著者名 Kitamura, Tetsuhisa
	NRID 1000000397671 1000000397671 ORCID 0000-0002-5618-4721 0000-0002-5618-4721 researchmap permalink C4589 C4589 Scopus Author ID 35395964700 35395964700 著者名 Sakata, Yasushi
内容	Sotomi Y., Matsuoka Y., Hikoso S., et al. P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Scientific Reports 13, 12608 (2023); https://doi.org/10.1038/s41598-023-39213-3.
抄録	It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis to evaluate P2Y12 inhibitor monotherapy vs. conventional DAPT in patients undergoing complex PCI and non-complex PCI (PROSPERO: CRD42022335723). Primary endpoint was the 1-year Net Adverse Clinical Event (NACE). Among 5,323 screened studies, six randomized trials fulfilled the eligibility criteria. A total of 10,588 complex PCI patients (5,269 vs. 5,319 patients) and 25,618 non-complex PCI patients (12,820 vs 12,798 patients) were randomly assigned to P2Y12 inhibitor monotherapy vs. conventional DAPT. In complex PCI patients, P2Y12 inhibitor monotherapy was associated with a lower risk of NACE than conventional DAPT [Odds ratio (OR) 0.76, 95% confidence interval (CI) 0.63–0.91, P = 0.003], whereas in non-complex PCI patients, P2Y12 inhibitor monotherapy was associated with a trend toward lowering the risk of NACE (OR 0.86, 95% CI 0.72–1.02, P = 0.09). This meta-analysis across randomized trials demonstrated that a strategy of short DAPT followed by P2Y12 inhibitor monotherapy reduces the risk of 1-year NACE in patients undergoing complex PCI.
出版者	Nature Research
収録物名	Scientific Reports
巻(号)	13(1)
ページ	12608
刊行年月	2023-08-03
言語	英語
ハンドルURL	https://hdl.handle.net/11094/94602
eISSN	20452322
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1038/s41598-023-39213-3
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Scientific Reports. 2023, 13(1), p. 12608
DC.title	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
DC.creator	Sotomi, Yohei
	Matsuoka, Yuki
	Hikoso, Shungo
	Nakatani, Daisaku
	Okada, Katsuki
	Dohi, Tomoharu
	Kida, Hirota
	Oeun, Bolrathanak
	Sunaga, Akihiro
	Sato, Taiki
	Kitamura, Tetsuhisa
	Sakata, Yasushi
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-08-03
DC.identifier	https://doi.org/10.1038/s41598-023-39213-3
DC.description	Sotomi Y., Matsuoka Y., Hikoso S., et al. P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Scientific Reports 13, 12608 (2023); https://doi.org/10.1038/s41598-023-39213-3.
DCTERMS.abstract	It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis to evaluate P2Y12 inhibitor monotherapy vs. conventional DAPT in patients undergoing complex PCI and non-complex PCI (PROSPERO: CRD42022335723). Primary endpoint was the 1-year Net Adverse Clinical Event (NACE). Among 5,323 screened studies, six randomized trials fulfilled the eligibility criteria. A total of 10,588 complex PCI patients (5,269 vs. 5,319 patients) and 25,618 non-complex PCI patients (12,820 vs 12,798 patients) were randomly assigned to P2Y12 inhibitor monotherapy vs. conventional DAPT. In complex PCI patients, P2Y12 inhibitor monotherapy was associated with a lower risk of NACE than conventional DAPT [Odds ratio (OR) 0.76, 95% confidence interval (CI) 0.63–0.91, P = 0.003], whereas in non-complex PCI patients, P2Y12 inhibitor monotherapy was associated with a trend toward lowering the risk of NACE (OR 0.86, 95% CI 0.72–1.02, P = 0.09). This meta-analysis across randomized trials demonstrated that a strategy of short DAPT followed by P2Y12 inhibitor monotherapy reduces the risk of 1-year NACE in patients undergoing complex PCI.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94602
citation_title	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
citation_author	Sotomi, Yohei
	Matsuoka, Yuki
	Hikoso, Shungo
	Nakatani, Daisaku
	Okada, Katsuki
	Dohi, Tomoharu
	Kida, Hirota
	Oeun, Bolrathanak
	Sunaga, Akihiro
	Sato, Taiki
	Kitamura, Tetsuhisa
	Sakata, Yasushi
citation_publisher	Nature Research
citation_language	英語
citation_date	2023-08-03
citation_journal_title	Scientific Reports
citation_volume	13
citation_issue	1
citation_firstpage	12608
citation_doi	https://doi.org/10.1038/s41598-023-39213-3
citation_public_url	https://hdl.handle.net/11094/94602

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

閲覧可能ファイル

論文情報

論文詳細を表示